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Introduction
Numerous factors are implicated in contributing to 
lifetime risk of developing breast cancer, including age, 
family history, age of menarche, age of menopause, and 
parity [1]. In addition to the multiple etiological factors 
that contribute to breast cancer risk, breast cancer is a 
disease with a wide spectrum of genetic alterations and 
phenotypic heterogeneity.
Breast cancers diagnosed in premenopausal women 
tend to be clinically unlike those diagnosed in the years 
following menopause. Th   ey are typically estrogen 
receptor negative (ER-), diagnosed at a higher stage, and 
often metastasize [2-5]. Premenopausal breast cancers 
can be categorized into hereditary breast cancers, includ-
ing those diagnosed in women with mutations in the 
BRCA1 or BRCA2 genes, or non-hereditary breast cancer 
[3]. Pregnancy-associated breast cancer (PABC) is a sub-
class of premenopausal breast cancer that is diag  nosed 
during pregnancy or following pregnancy [6-9]. Currently 
there is no consensus on the time frame of PABC diag-
nosis. Some researchers and clinicians limit PABC to the 
diagnosis of cancer during pregnancy while others include 
cases diagnosed within 10 years following preg  nancy. 
When compared to non-PABC cases, women diag  nosed 
with PABC are typically diagnosed at a later stage, are 
commonly ER-, and also have a worse prognosis [8,10-13].
In contrast, breast cancers diagnosed following meno-
pause are predominantly ER-positive (ER+), respond 
better to current therapies, and confer an overall better 
patient prognosis, except for breast cancers diagnosed in 
obese individuals [14,15]. In postmenopausal but not 
premenopausal women, obesity is linked with a further 
increased risk of developing breast cancer. Th  eses  cancers 
are diagnosed at a later stage, are more aggressive tumors 
and exhibit a worse overall patient survival rate [16,17].
Th  e molecular and cellular diﬀ  erences between pre-
menopausal and postmenopausal breast cancers remain 
largely unknown. In principle, the cellular origins of 
premenopausal and postmenopausal cancers might diﬀ  er. 
Alternatively, it could be that the inherent genetic or 
epigenetic alterations sustained within the same epi-
thelial target population diﬀ  er depending on the develop-
mental stage or age of the breast epithelium. However, 
since there are substantial stromal and hor  monal 
diﬀ   erences within premenopausal breast tissues com-
pared to postmenopausal tissues, it is highly plausible 
that the inﬂ  uences of the microenvironment may also be 
equally important in the etiology of these diﬀ  erent 
diseases. In this review, we will discuss the changes that 
occur throughout mammary gland development and 
focus on how diﬀ  ering stromal microenvironments might 
promote the formation of diﬀ  erent subtypes of breast 
cancer.
Abstract
Breast cancer is a heterogeneous disease whose 
prognosis varies depending upon the developmental 
stage of the breast tissue at diagnosis. Notably, breast 
cancers associated with pregnancy exhibit increased 
rates of metastasis and poorer long-term survival 
compared to those diagnosed after menopause. 
However, postmenopausal breast cancers associated 
with obesity exhibit a     more aggressive behavior and 
confer decreased overall patient survival compared to 
those diagnosed in non-obese individuals. Since the 
mammary gland is a dynamic tissue that undergoes 
signifi  cant changes throughout a woman’s lifetime, 
especially during pregnancy and following menopause, 
we present evidence to support the notion that 
changes occurring throughout development within 
the mammary stromal compartment may account 
for some of the biological diff  erences in breast cancer 
subtypes and behaviors.
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Overview
It is well established that one full term pregnancy reduces 
a woman’s lifetime risk of developing breast cancer 
[18-21]. However, the extent of this protection is depen-
dent upon age of the ﬁ  rst pregnancy. Pregnancy before 
the age of 20 confers the greatest protection, but for each 
year that pregnancy is delayed, there is a 3.5% increase in 
breast cancer risk [22]. Furthermore, women who delay 
childbearing until after age 35 are not protected from 
breast cancer; rather, they are actually at an increased 
lifetime risk of developing breast cancer compared to 
nulliparous women [23,24]. Th   e increasing trend to delay 
childbearing has resulted in an increase in the diagnosis 
of PABC cases [13]. Since the diagnosis of PABC is 
predicted to increase, we will focus our discussion of pre-
meno  pausal breast cancers on PABC in this review.
Stroma of pregnancy and lactation
Th  e breast mesenchyme is a complex connective tissue 
composed of heterogeneous cell types, including ﬁ  bro-
blasts, adipocytes, immune cells, endothelial cells, peri-
cytes, nerve cells and acellular matrix components, such 
as collagen I, III, IV, proteoglycans, and glyco  proteins 
[25]. During pregnancy, there is signiﬁ  cant remodeling of 
the breast stromal tissue to accommodate the needs of 
the expand  ing epithelium. Th   is remodeling includes the 
generation of new blood vessels (angiogenesis), inﬁ  ltra-
tion of immune and inﬂ  ammatory cells, ﬁ  broblast reorga-
ni  zation and the loss of lipid droplets within adipocytes 
[26,27], all of which are necessary to supply nutrients and 
cues to the changing epithelial demands but may contri-
bute to the development of breast cancer [28,29].
In addition to the extensive stromal remodeling occur-
ring in the mammary gland during pregnancy, there are 
drastic increases in circulating hormones, production of 
localized growth factors, and substantial expansion of the 
epithelial tree. Since breast carcinoma cells that express 
ER proliferate faster in response to gestational hormones, 
one hypothesis to explain the transient increase in breast 
cancer risk following pregnancy is the eﬀ  ect of systemic 
hormones such as estrogen and progesterone, both of 
which are greatly elevated during pregnancy, on promot-
ing the growth of initiated cancer cells. However, most 
PABCs lack appreciable expression of either the ER or 
progesterone receptor [30,31]. Th   is important observa  tion 
suggests that if hormones like estrogen or progesterone 
are involved in promoting breast cancer following 
pregnancy, they may not be doing so through direct 
binding to cognate receptors expressed by breast epithe-
lial cells.
In fact, recent studies using a xenograft model of 
PABC, in which tumor cells lacked expression of ER and 
progesterone receptor, demonstrated that the stroma 
played an active role in promoting ER- tumor growth in 
response to systemic hormones [32]. In response to treat-
ment with exogenous estrogen, bone marrow derived 
macrophages, immune cells and ﬁ  broblasts, as well as 
non-bone marrow derived ﬁ  broblasts, adipocytes, peri-
cytes and endothelial cells, were all recruited to the 
stroma at sites of angiogenesis and tumor growth, 
resulting in enhanced tumorigenesis. Th  e  authors 
concluded that estrogen enhanced growth of tumors by 
inﬂ  uencing the physiology of the host tissue rather than 
direct eﬀ  ects on the carcinoma cells.
Although abundant in the non-pregnant mammary 
gland, adipocytes begin to lose their lipid content and 
become less visible during late pregnancy and represent a 
small proportion of the overall gland by lactation. Despite 
this remarkable change in adipocyte content and pro-
portion, the precise role of adipocytes in normal breast 
development remains unclear. Th   e role of the adipocyte 
in premenopausal breast cancer is also understudied. As 
we will discuss below, obesity is a risk factor speciﬁ  cally 
for postmenopausal women [33], and as such, the 
majority of research conducted on adipocytes and cancer 
is in postmenopausal women. However, new evidence 
suggests that leptin, a cytokine secreted by adipocytes, 
can stimulate breast cancer growth in both estrogen-
dependent (ER+) and estrogen-independent (ER-) cells 
[34] and may, therefore, also be important for the patho-
genesis of premenopausal breast cancer.
Another cell type recruited to the mammary gland 
during pregnancy and lactation are macrophages. Th  ey 
are recruited from the bone marrow in response to the 
secretion of colony stimulating factor-1 (CSF-1) and 
associate with the elongating ducts during puberty and 
the lobulo-alveoli in pregnancy [35]. CSF-1 regulates the 
proliferation, survival and migration of macrophages 
[36]. Interestingly, mice lacking CSF-1 exhibit decreased 
numbers of recruited macrophages and display preco-
cious development of lobulo-alveolar structures by mid-
pregnancy, increasing further on day 18 of preg  nancy 
(twice the normal size). Restoration of CSF-1 levels in 
these mice restored normal numbers of macrophages and 
normal tissue architecture, suggesting that macro  phages 
alone are not suﬃ     cient for proper mammary gland 
develop  ment. CSF-1 may also contribute to the aggres-
sive nature of ER-negative breast cancer cells. Use of 
blocking antibodies that speciﬁ  cally inhibit the recep  tor 
to CSF-1 in an animal model of aggressive breast cancer 
reduced tumor cell invasion in vivo, indicating that the 
paracrine interactions between host macrophages and 
breast cancer cells are involved in tumor cell invasion [37].
Given the extensive stromal remodeling occurring in 
the mammary gland during pregnancy, there are many 
possible factors that could fuel tumor growth. Further 
research will be necessary to fully understand the role 
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involved during this stage of development. Further 
insight into the cellular and molecular factors that 
regulate stromal development might also provide a 
greater understanding of how these cells participate and 
promote cancer formation and progression.
Stroma of post-lactational involution
Upon weaning, considerable stromal remodeling is 
required for proper regression of the epithelium during 
post-lactational involution. Th   is stage is characterized by 
recruitment of immune cells, regression of the expanded 
vasculature, degradation of extracellular matrix (ECM) 
and the re-appearance of lipid ﬁ  lled adipocytes [27,38]. 
Th  e  ﬁ  rst stage of post-lactational involution is directed by 
loss of suckling, resulting in milk stasis, and is 
characterized by the apoptosis of epithelial cells. Th  e 
accumulation of milk in the epithelial cells stimulates the 
release of both leukemia inhibitory factor (LIF) and 
trans  forming growth factor β3 (TGFβ3) from the 
epithelium in the mammary gland. LIF expression levels 
peak in the mammary gland during the ﬁ  rst phase of 
involution, resulting in a signiﬁ  cant increase in epithelial 
cell apoptosis [39,40]. Epithelial cell apoptosis is also 
caused by the induction of TGFβ3 in response to milk 
stasis. Other cytokines are upregulated during post-lacta-
tional involution, such as FasL [41], IL-6 [42], and IL-10 
[43]. Inhibition of any of these factors delays the onset of 
involution. Mice deﬁ  cient in TGFβ3 also exhibit a delayed 
onset of apoptosis during post-lactational involu  tion, 
suggesting it is a requisite factor for epithelial cell 
apoptosis in this phase of mammary gland development 
[44]. Indeed, the onset of post-lactational involution is 
accelerated by its premature expression. Additionally, the 
upregulation of a number of cell death pathways is also 
important for the ﬁ  rst phase of post-lactational involu-
tion. p53, bax and bcl2 expression are all necessary 
components for the proper timing of the ﬁ  rst phase of 
involution [45-47].
Th   e second, irreversible phase of post-lactational 
involution is characterized by the collapse of glandular 
tissue structure and stromal remodeling changes that 
parallel the molecular and cellular changes associated 
with wound healing. For example, matrix metallo-
proteinase (MMP) expression becomes elevated in the 
mammary stroma around day 4 of involution, resulting in 
a multitude of cellular responses. MMPs degrade the 
basement membrane and the surrounding ECM, 
resulting in the breakdown of the matrix components as 
well as the release of ECM-embedded cytokines such as 
TGFβ, IL1-β, and TNFα [48]. Th   is destabilization of the 
epithelial cells may cause detachment-induced apoptosis 
(anoikis) and further regression of the expanded lobulo-
alveoli [49].
As epithelial cells are systematically removed from the 
mammary gland, adipocytes begin to reﬁ  ll with lipid and 
repopulate the stromal fat pad. Interestingly, MMP3, 
which is required for proper adipocyte maturation [50], 
is increased over 50-fold during post-lactational involu-
tion when compared to pregnant or lactating mammary 
glands. Th   e precise cell type in the stroma that produces 
MMP3 has not been determined, nor has the precise role 
of MMP3 been fully elucidated. In fact, MMP3 knockout 
mice exhibit accelerated involution due, in part, to the 
rapid repopulation of adipocytes in the gland. Moreover, 
inhibition of MMP3 through overexpression of TIMP1 
also accelerated the repopulation of adipocytes following 
involution. Th  ese mice contained approximately 40% 
more unilocular adipocytes when compared to control 
mice [50]. However, it is surprising that MMP3 trans-
genic mice also exhibit premature involution [51]. Th  is 
latter observation could be reconciled by the fact that 
premature disruption of basement membrane integrity 
by any ECM-degrading enzyme could accelerate mammary 
epithelial cell death.
Th  e elevated levels of MMP3 expression during post-
lactational involution are also attendant with elevated 
entactin and platelet/endothelial cell adhesion molecule 
(PECAM) expression; entactin is enriched in the base-
ment membrane of adipocytes, while PECAM is expressed 
by endothelial cells in capillaries and blood vessels. Th  e 
synchronized expression of MMP3, entactin and PECAM 
indicates the orchestrated nature of stromal cell re-
modeling: mature adipocytes are repopulating the involu-
ting mammary gland at the same time that new blood 
vessels are forming, allowing contact between endo  thelial 
cells and adipocytes.
Consistent with the notion that mammary gland 
involution mimics tissue remodeling associated with 
wound healing, it is not surprising that various types of 
immune and inﬂ  ammatory cells inﬁ  ltrate the mammary 
gland during involution. Immunohistochemistry of invo-
lut  ing murine mammary glands indicates that leukocytes, 
neutrophils, macrophages and plasma cells are abundant 
[52]. Th   ese cells are thought to play a role in the homeo-
stasis of the normal mammary gland by actively suppres-
sing inﬂ  ammation but further research is necessary to 
conﬁ  rm their role in involution.
Th   e breast tissue microenvironment during post-lacta-
tional involution may also contribute to an increase in 
risk of PABC [53]. As discussed above, the mammary 
gland undergoes dramatic physical remodeling after 
lactation and many of the steps required for this process 
provide an ideal environment for breast cancer growth 
and progression. Co-injection of MDA-MB231 cancer 
cells with extracellular matrix derived from involuting 
mammary tissues resulted in a higher rate of metastasis 
to the lung, liver and kidney [53]. Tumors grown with the 
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contained higher levels of vascular endothelial growth 
factor (VEGF). Additionally, ECM isolated from involut-
ing mammary glands contained elevated levels of activated 
MMP2, 3, and 9 when compared to the matrix isolated 
from nulliparous glands [54], further explaining the 
increase in metastasis and elevated tumor VEGF levels.
Th   e changes in extracellular matrix within the involut-
ing mammary tissues are mediated, in part, by macro-
phages that are actively recruited to the gland. In breast 
cancer tissues, recruited macrophages correlate with 
early relapse and decreased patient prognosis [55]. Th  ese 
cells secrete pro-angiogenic cytokines such as VEGF, 
TNFα, IL6, and granulocyte colony stimulating factor, all 
of which have been suggested to promote angiogenesis 
[56]. In fact, macrophage inﬁ   ltration preceded angio-
genesis in a mouse model of human breast cancer and 
failure to recruit macrophages delayed the angiogenic 
switch and subsequent tumor progression [57]. Given the 
important role of macrophages in tumor formation and 
progression, the recruitment of macrophages during 
both pregnancy and involution of patients aﬄ   icted with 
PABC may enhance pre-neoplastic changes that have 
already taken place in the breast.
Postmenopausal breast cancer
Overview
Breast cancer incidence increases with age, but plateaus 
at a time that coincides with the onset of menopause [58]. 
When stratiﬁ  ed for ER status, ER- breast cancer inci-
dence plateaus following menopause while the incidence 
of ER+ tumors continues to rise [5]. Moreover, there is a 
further increased risk of developing ER+ breast cancers 
in postmenopausal women with a body mass index 
greater than 30 [59,60]. Indeed, postmenopausal breast 
cancers (obesity-associated or otherwise) are generally 
ER+ and respond to anti-hormone therapies [61,62]. Th  is 
increased incidence of ER+ breast cancers has been 
attributed, in part, to the increased levels of estrogen 
produced in fat depots [63]. Androgens which are 
primarily of adrenal origin remain constant following 
menopause, but are metabolized to estrogen in peripheral 
adipose tissues by aromatase (reviewed in [64]). Th  us,  the 
increased levels of local estrogen [65] might lead to the 
overall increased risk of breast cancer. However, breast 
stromal tissue is a reservoir of subcutaneous fat. Th  is 
adipose tissue has largely been ill-deﬁ  ned in the study of 
breast cancer, and in the background of the obese and 
post-menopausal state, the change in tissue constitution 
may have a profound eﬀ  ect on breast cancer development 
and progression. In addition, many other changes are 
taking place in the breast following menopause that could 
equally participate in promoting and accelerating tumor 
formation [66].
Stroma of lobular involution
In humans, menopause is characterized by the cessation 
of estrogen and progesterone production by the ovaries 
and the end of menstruation. Th   ese systemic endocrine 
changes coincide with an irreversible process that has 
been termed lobular involution in which the number and 
size of the lobules are reduced [67]. Furthermore, the 
number of ER-expressing breast epithelial cells increases 
dramatically: only approximately 10% of epithelial cells 
within lobules and ducts of premenopausal tissues 
express ER, while nearly 90% of cells within involuted 
postmenopausal breast tissues are ER+ [68]. In addition 
to epithelial attrition, the intralobular stroma of breast 
tissue is replaced with dense collagen connective tissue 
[69], and interlobular stroma is replaced with adipose 
tissue [70].
Mammographic density (MD) has routinely been used 
to measure the changes in tissue composition following 
menopause. Postmenopausal breast tissues are associated 
with lower MD, indicative of increased fatty tissue, while 
areas that have a higher density, representing the 
ﬁ   broblastic and epithelial portions of the breast, are 
greater in premenopausal breast tissues [71,72]. Breast 
tissue composition as measured by MD is an important 
risk factor for the development of breast cancer [73,74]. 
Involvement of 60% or more of the breast tissue with 
mammographically dense tissue confers a three- to ﬁ  ve-
fold increased relative risk for breast cancer, similar to 
the increase in risk conferred by having an inherited 
mutation in the breast cancer gene BRCA1 [75,76].
Changes in the ECM composition in postmenopausal 
breast tissue may contribute to an increase in breast 
cancer risk as measured by an increase in MD. In a study 
of mostly postmenopausal women, patients with high 
MD had an increase in collagenous stroma [77] as well as 
an increase in the expression of lumican and decorin 
[78]. Fibrillar collagens are one of the most important 
ECM proteins in determining stromal architecture. 
Stromal integrity, including ﬁ  bril spacing, is determined 
by lumican and decorin; therefore, an increase in MD 
similar to that seen in breast cancer patients may reﬂ  ect 
changes in the composition of ECM proteins and 
mammary stroma. Th  ese changes may inﬂ  uence  early 
events in tumorigenesis; however, further experiments 
are needed to determine possible mechanisms.
Several studies have been conducted to correlate 
genetic and environmental factors with breast MD. In 
particular, it has been suggested that the increased risk of 
breast cancer due to hormone replacement therapy in 
postmenopausal women is attributable, in part, to its role 
in increasing MD [79]. Consistent with this notion, 
recent experiments have demonstrated that systemic 
estrogen was suﬃ   cient to increase tissue stromalization, 
cellular density, and angiogenesis [32]. Moreover, women 
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decreased MD [80]. Th  us, decreasing circulating estro-
gens or inhibiting ER activation may have dual roles in 
inhibiting breast cancer progression by decreasing the 
proliferative potential of expanded ER+ breast epithelial 
cells, which would directly reduce the potential growth of 
premalignant or malignant cells, and by decreasing 
stromal cellularity and ﬁ  brous density, which may reduce 
the tumor-promoting eﬀ  ects of the surrounding micro-
environment. However, additional clinical and experi-
mental studies are needed to further understand the 
molecular and cellular connection between systemic 
hormones, MD and breast cancer.
Stroma associated with obesity
Age-related menopause is associated with increased 
visceral adiposity. Women who are obese are at a further 
increased risk of developing breast cancer [60,61]. Breast 
cancers associated with obesity are diagnosed at a later 
stage [81] and are more aggressive [82-84] when com-
pared to breast cancer diagnosed in non-obese women. 
While the majority of breast cancers associated with 
obesity are ER+, some of them are ER-.
Adipose tissue in both the lean and obese state appears 
to have a signiﬁ  cant impact on the development of breast 
cancer and its prognosis. Adipocytes are potent endo-
crine cells that produce a variety of hormones and growth 
factors that diﬀ  er between the lean and obese state. It is 
now recognized that the inﬁ  ltration and pro-inﬂ  amma-
tory activation of immune cells in adipose tissue underlie 
obesity complications [85-87]. Th   e obese state is accom-
panied by a dramatic inﬂ   ux of macrophages in the 
adipose tissue, resulting in an inﬂ  ammatory state that is 
thought to promote local and systemic insulin resistance 
[86,88-90]. Th  e inﬂ   ux of macrophages is thought to 
result, in part, from increased expression of monocyte-
chemoattractant protein-1 (MCP-1) in obese adipose 
tissue, which is well known to recruit monocytes. 
Consistent with this notion, knockout of MCP-1 or its 
receptor, CCR2, in mice reduces macrophage inﬁ  ltration, 
and protects against obesity-induced inﬂ  ammation  in 
adipose tissue [86,88,89,91].
Manifestations of the inﬂ   ammatory state found in 
adipose tissue with obesity include increased expression 
of cytokines and factors such as TNFα, TGFβ, IL1β and 
hepatocyte growth factor [92,93]. Chronic inﬂ  ammation 
itself is a potent tumor promoter of many cancers, 
including breast cancer [94], and both TGFβ and 
hepatocyte growth factor have been implicated in the 
development of breast cancer [92,93,95].
Th  e mechanisms by which inﬂ   ammation occurs in 
adipose tissue remain unclear. However, it has been 
demon  strated that adipocytes release factors that can 
activate macrophages, resulting in the release of 
cyto  kines [96,97]. One obvious candidate for activating 
macrophages is fatty acids. Adipocytes release fatty acids 
as a byproduct of lipolysis. It has been demonstrated that 
saturated fatty acid and endotoxin can both bind and 
activate toll receptor 4 (TLR-4) on macrophages [98,99]. 
Palmitate is one of the major fatty acids that circulate in 
the body [100]; thus, release of palmitate in an obese state 
can bind and activate TLR-4, resulting in release of 
cytokines such as TNFα. Th   e release of TNFα then acts 
in a paracrine and autocrine fashion on adipocytes to 
increase rates of lipolysis [101], resulting in further 
release of fatty acids and activation of macrophages. 
Th   us, macrophages and adipocytes interact in adipose to 
promote a cycle of inﬂ  ammation and lipolysis.
Leptin is another hormone that is predominantly 
produced by adipose tissue. Its expression levels correlate 
with body fat and its levels are particularly high in obese 
women [102]. Secretion of leptin creates a micro  environ-
ment that is favorable to an aggressive breast cancer. It 
stimulates tumor cell growth and invasion as well as 
angiogenesis [103]. High levels of circulating leptin, 
similar to those seen in obese women, cause an increase 
in breast cancer proliferation through the activation of 
the mitogen-activated protein kinase and phosphatidyl-
inositol 3-kinase signaling pathways [104].
Adipocytes also secrete adiponectin (APN), whose 
levels have been inversely correlated with obesity [105] 
and breast cancer risk [106], suggesting that the increased 
risk of developing breast cancer in obese postmenopausal 
women may be due to a reduction in APN levels. 
Cytokines such as TNFα have been implicated in the 
obesity-associated reduction in adipocyte expression of 
APN and increased release of adipocyte fatty acids. In the 
obese state, there is a reduction of APN and increased 
release of fatty acids in the blood, which are thought to 
be critical in the development of obesity-associated 
insulin resistance, and insulin resistance itself is 
implicated in cancer development.
Table 1. Clinical characteristics of developmental stage-
specifi  c breast cancers
 Increased  risk
Stage  (tumor subtype)*  Clinical characteristics
Pregnancy  ER-  High stage diagnosis
   High  grade
   Often  metastatic
Postmenopause  ER+  Lower grade at diagnosis
    Respond to anti-hormone therapies
Postmenopause   ER-  High stage diagnosis
with obesity    Poor patient survival rate
*According to [5,10,30].
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promoter-driven polyoma middle T oncogene (MMTV-
PyMT) model in an APN-/- background show reduced 
tumor growth only at the early stages of tumor develop-
ment due to impaired tumor angiogenesis, consistent 
with the role of APN in blood vessel remodeling [98,107]. 
As the tumor progresses, tumor burden signiﬁ  cantly 
increases in APN-/- mice due to a mobilization of 
endothelial precursor cells and subsequent restoration of 
impeded angiogenesis [107].
Collagen VI is also abundantly produced within 
adipose tissue [108] and upregulated during the progres-
sion of mouse mammary tumors [109]. MMTV-PyMT 
mice in a collagen VI-/- background have signiﬁ  cantly 
reduced tumor burden and increased tumor latency 
compared to MMTV-PyMT collagen VI+/+ mice. Th  e 
promotion of mammary tumor growth by adipocyte-
derived collagen VI is mediated by Akt, β-catenin, and 
cyclin D1 signaling [110]. Since both APN and collagen 
VI null mice display delayed tumor development in an 
MMTV-PyMT background, these studies suggest that 
adipocyte-derived factors may inﬂ   uence the initiation 
and/or early progression of breast tumors. Th  ey also 
provide evidence that may explain the increase in risk of 
postmenopausal breast cancer in obese individuals.
Recent studies have also revealed that stromal stem 
cells isolated from fat depots in obese mice promote 
angiogenesis and tumor progression [111]. Th  is  suggests 
that in addition to the changes in cytokine production, 
the cellular constituents of adipose tissue are diﬀ  erent 
from those of typical fat depots. However, it is unclear 
what molecular and epigenetic diﬀ  erences exist between 
stromal stem cells from obese and non-obese mice; thus, 
additional studies need to be designed to understand the 
role of these cells in postmenopausal associated obesity.
Conclusion
Th  ere are distinct diﬀ  erences in the composition of the 
stroma at diﬀ  erent stages of breast development, which 
correlate with the biological characteristics of breast 
cancer subtypes and patient prognosis. PABCs have 
diﬀ  erent characteristics from breast cancers diagnosed in 
non-obese postmenopausal women, which also are 
somewhat diﬀ  erent from those diagnosed in postmeno-
pausal obese women (Table 1). For example, PABC and 
postmenopausal breast cancer associated with obesity 
are both diagnosed at a later stage, do not respond well to 
current therapies and confer an overall poorer patient 
prognosis. Analysis of the mammary microenvironment 
during pregnancy as well as the microenvironment of the 
adipose tissue associated with obesity reveals similarities 
that may account for these parallels (Table  2). Both 
involve the release of cytokines from adjacent stromal 
cells, thereby creating an inﬂ  ammatory microenvironment 
that promotes angiogenesis, matrix remodeling and 
tumorigenesis. Macrophages are recruited into the 
mammary gland during remodeling associated with 
pregnancy as well as to the breast in postmenopausal 
obese women. Factors promoting angiogenesis are preva-
lent in both the involuting mammary gland as well as in 
the postmenopausal obese gland. Th   e factors secreted by 
stromal cells that promote angiogenesis in the two stages, 
however, are not identical. For example, in the involuting 
mammary gland, recruited macrophages secrete pro-
angiogenic factors such as VEGF and IL-6, while in the 
postmenopausal obese mammary gland, adipocytes 
secrete the pro-angiogenic hormone leptin and decrease 
the secretion of anti-angiogenic adiponectin. It is not 
surprising that stromal cells in diﬀ   erent stages of 
develop  ment would secrete diﬀ   erent factors, but it is 
interesting to suggest that in each case the stroma is 
responsible for promoting tumors with similar clinical 
and biological characteristics.
Current therapies target primarily the carcinoma cells; 
however, many women develop recurrent disease and/or 
distant metastases following treatment. Given the suppor-
tive and instructive role of the stroma in cancer progression, 
identifying therapeutics tailored to both the stroma and 
epithelium may have more clinical eﬃ   cacy for prevention of 
local recurrence and prevention of metastases.
Abbreviations
APN = adiponectin; CSF = colony stimulating factor; ECM = extracellular 
matrix; ER = estrogen receptor; IL = interleukin; LIF = leukemia inhibitory 
factor; MD = mammographic density; MMP = matrix metalloproteinase; 
PABC = pregnancy-associated breast cancer; PECAM = platelet/endothelial cell 
adhesion molecule; TGF = transforming growth factor; TNF = tumor necrosis 
factor; VEGF = vascular endothelial growth factor.
Table 2. Microenvironmental characteristics of developmental stage-specifi  c breast cancers
Stage  Stromal changes  Growth factors/matrix
PABC  Macrophage recruitment, infl  ammation, angiogenesis,   ECM degradation, MCP-1, CSF-1, IGF, HGF, TGF beta, 
  adipocyte remodeling  systemic estrogen
Postmenopause  Aromatase, epithelial atrophy, stromal replacement,   Local estrogen, lumican, decorin, collagen
 adipocyte  remodeling 
Postmenopause with obesity  Macrophages, infl  ammation, angiogenesis, aromatase,   IGF, HGF, MCP-1, TGF beta, local and systemic estrogen
 reactive  adipose 
CSF-1, colony stimulating factor-1; ECM, extracellular matrix; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor 1; MCP-1, monocyte-chemoattractant 
protein-1; PABC, pregnancy-associated breast cancer; TGF, transforming growth factor.
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